Horizon Therapeutics (NQ: HZNP )

69.04 USD UNCHANGED

Streaming Delayed Price Updated: 7:59 PM EST, Nov 24, 2020 Add to My Watchlist

Price and Volume

Volume	0
Open	69.04
Bid (Size)	69.23 (1)
Ask (Size)	72.00 (1)
Prev. Close	69.04
Today's Range	69.04 - 69.04
52wk Range	23.81 - 86.67
Shares Outstanding	118,852,790
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

November 23, 2020

- Horizon to use ENHANZE® subcutaneous delivery technology for TEPEZZA® (teprotumumab-trbw) -

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

November 23, 2020

Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme’s...

Performance

YTD	+89.77%	+89.77%
1 Month	-10.65%	-10.65%
3 Month	-6.35%	-6.35%
6 Month	+39.98%	+39.98%
1 Year	+112.37%	+112.37%

More News

National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation

November 17, 2020

First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease

November 16, 2020

New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration

November 13, 2020

Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala

November 13, 2020

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

November 12, 2020

Noteworthy ETF Inflows: VBK, HZNP, ZBRA, PODD

November 23, 2020

Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil

November 02, 2020

FTXH's Holdings Could Mean 18% Gain Potential

November 17, 2020

Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA

November 02, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.